Today: 28 June 2026
Browse Category

NASDAQ:GBT 16 August 2025 - 18 August 2025

Biotech, Pharma, and Health Breakthroughs You Missed on August 17–18, 2025

Biotech, Pharma, and Health Breakthroughs You Missed on August 17–18, 2025

The FDA approved Tonix’s Tonmya as the first new fibromyalgia drug in over 15 years. Novo Nordisk’s Wegovy received accelerated FDA approval for MASH, becoming the first GLP-1 therapy cleared for the liver disease. Pfizer’s sickle cell drug inclacumab failed a Phase 3 trial, marking another setback after its $5.4 billion Global Blood Therapeutics acquisition. Eli Lilly announced a $1.3 billion AI drug partnership with Superluminal.
18 August 2025
·····
Breakthrough Cures, Big Deals, and Global Health Alerts – Biotech & Health News Roundup (Aug 16–17, 2025)

Breakthrough Cures, Big Deals, and Global Health Alerts – Biotech & Health News Roundup (Aug 16–17, 2025)

Pfizer’s sickle cell drug inclacumab failed a Phase 3 trial, missing its main goal and deepening setbacks from its $5.4 billion Global Blood Therapeutics acquisition. In contrast, Pfizer and Merck’s Padcev-Keytruda combo improved survival in muscle-invasive bladder cancer. Novo Nordisk’s Wegovy won FDA approval for treating metabolic dysfunction-associated steatohepatitis.
17 August 2025
······
Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

Wegovy became the first GLP-1 therapy approved by the FDA for MASH, affecting about 5% of U.S. adults. Tonix’s Tonmya was cleared for fibromyalgia, the first new therapy in 15 years. Pfizer’s inclacumab failed a key sickle cell trial, and Oxbryta was withdrawn. BioNTech agreed to acquire CureVac in a $1.25 billion all-stock deal.
16 August 2025
··········

Stock Market Today

  • Ripple's Preliminary EU MiCA Approval Raises Questions on RLUSD and XRP Impact in Europe
    June 28, 2026, 12:06 PM EDT. Ripple received a preliminary Luxembourg crypto-asset service provider (CASP) license under the EU's Markets in Crypto-Assets (MiCA) framework, allowing it to offer regulated services across 30 EEA countries pending final conditions. Despite this regulatory milestone, investors remain cautious about the XRP token's value driver, as Ripple's license ownership does not directly translate to increased activity on the XRP Ledger (XRPL). While Ripple's regulated stablecoin RLUSD's supply declined over 30 days, XRPL stablecoin value grew by over 20%, challenging XRP's current $1.05 price near a $65.5 billion market cap. The EU's July 1, 2026, MiCA enforcement deadline heightens the license's strategic importance, but tangible XRP Ledger usage remains the critical question for investors assessing Ripple's European payments push.

Latest articles

MSFT rally set for Russell reshuffle as AI spending jitters hang over stock

MSFT rally set for Russell reshuffle as AI spending jitters hang over stock

28 June 2026
Microsoft (MSFT) surged 5.71% to $372.97 on record volume as FTSE Russell index changes moved the stock into both growth and value indexes, driving a “really massive trade” and “key liquidity day”; investors now face uncertainty over real demand versus index flows, with capex and AI spending weighing on future profitability.
Amazon (NASDAQ:AMZN) trades after Prime Day jump, AWS in focus as basket sizes shrink

Amazon (NASDAQ:AMZN) trades after Prime Day jump, AWS in focus as basket sizes shrink

28 June 2026
Amazon closed Friday at $232.69, up 2.5% on massive volume, but still down 4.8% from June 18; Prime Day U.S. sales jumped 9.3% to $26.4 billion as average order size fell 10.6%, while AWS will raise AI compute prices by about 20% in July, spotlighting investor focus on whether higher AWS pricing can offset soaring AI infrastructure costs.
Go toTop